7.93
0.28 (3.66%)
| Previous Close | 7.65 |
| Open | 7.53 |
| Volume | 63,746 |
| Avg. Volume (3M) | 328,114 |
| Market Cap | 185,094,176 |
| Price / Book | 0.110 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -47.14 |
| Total Debt/Equity (MRQ) | 9.23% |
| Current Ratio (MRQ) | 2.56 |
| Operating Cash Flow (TTM) | -13.34 M |
| Levered Free Cash Flow (TTM) | -7.53 M |
| Return on Assets (TTM) | -157.06% |
| Return on Equity (TTM) | -490.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | TransCode Therapeutics, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company’s lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 0.71% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Private Capital Management Llc | 31 Dec 2024 | 0 |
| 52 Weeks Range | ||
| Median | 10.00 (26.11%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 16 Apr 2025 | 10.00 (26.10%) | Buy | 10.00 |
| 13 Mar 2025 | 20.00 (152.21%) | Buy | 20.78 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |